Close

FDA calls for strictest warning on drug linked to brain infection

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

FDA Aims to Decrease Animal Testing as Tech Gathers Pace

Drug developers are raising the adoption of AI technologies...

$2 Billion Expansion By J&J in North Carolina Facility

Johnson & Johnson on August 21, 2025, went on...

Pharma Sector Reactions to US-EU Trade Framework Deal

The United States and the EU have, on August...

Chinese Pharmaceutical Firms Turn to Local Reagent Suppliers

The Chinese pharmaceutical firms are increasingly looking out for...

The US Food and Drug Administration plans to strengthen the warning label on lymphoma drug Adcetris over concerns that it may be linked to a rare, but deadly brain infection.

At the time of approval in August 2011, the regulator had seen one case of progressive multifocal leukoencephalopathy (PML) in a patient who had taken the drug, marketed by Seattle Genetics and Takeda Pharmaceutical. Since then, two more cases have been reported and the FDA is requiring a boxed warning – its strictest warning – to be placed on Adcetris’ label. The regulator has also warned that Adcetris should not be taken with cancer drug bleomycin due to increased risk of lung toxicity. Seattle Genetics must now conduct follow-up studies to confirm the safety of the treatment.

In 2011, Adcetris became the first drug to be approved by the FDA for the treatment of Hodgkins in 30 years. The drug also treats a rare disease known as systemic anaplastic large cell lymphoma.

Chief medical officer Thomas Reynolds said in a statement, “Although PML in lymphoma patients can be caused by factors such as underlying disease and prior therapies that affect the immune system, a contributory role of Adcetris cannot be excluded.”

Latest stories

Related stories

FDA Aims to Decrease Animal Testing as Tech Gathers Pace

Drug developers are raising the adoption of AI technologies...

$2 Billion Expansion By J&J in North Carolina Facility

Johnson & Johnson on August 21, 2025, went on...

Pharma Sector Reactions to US-EU Trade Framework Deal

The United States and the EU have, on August...

Chinese Pharmaceutical Firms Turn to Local Reagent Suppliers

The Chinese pharmaceutical firms are increasingly looking out for...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back